Long term elevations in plasma thyrotropin, but not growth hormone, concentrations associated with lesion-induced depletion of median eminence somatostatin
- PMID: 6129135
- DOI: 10.1210/endo-112-2-659
Long term elevations in plasma thyrotropin, but not growth hormone, concentrations associated with lesion-induced depletion of median eminence somatostatin
Abstract
Evidence suggests that somatostatin (SRIF) inhibits nonstress GH and TSH secretion and suppresses GH secretion in response to stress. The aims of this study were to determine whether placement of lesions in the hypothalamic periventricular (PV) nucleus, the location of SRIF neurons which seem to be responsible for most median eminence SRIF, causes elevation of nonstress plasma GH and TSH levels and blocks stress-induced suppression of these hormones. Electrolytic lesions were placed in female rats, and blood was obtained for assessing nonstress and stress plasma levels of GH and TSH at several intervals after surgery until autopsy, 56 weeks after surgery, when median eminences were collected. PV lesions produced only transient elevation of nonstress plasma GH levels and failed to block the suppression of GH secretion by stress. In contrast, PV lesions caused long term elevation of nonstress plasma TSH levels and blockade of stress-induced suppression of TSH secretion. The content and concentration of SRIF in the median eminence were reduced 90% in the PV-lesioned group. These data demonstrate that PV lesions, which result in marked depletion of median eminence SRIF, can cause long term elevations of plasma TSH levels and disruption of the TSH response to stress without producing alterations in GH secretion. Thus, the hypothalamic PV nucleus, its SRIF neurons and most median eminence SRIF are not essential for maintaining normal GH secretion, but seem to be involved in the regulation of TSH release. It appears that different brain structures are involved in inhibiting GH and TSH secretion.
Similar articles
-
Effects of hypothalamic periventricular lesions on pulsatile growth hormone secretion.Neuroendocrinology. 1985 Nov;41(5):357-62. doi: 10.1159/000124202. Neuroendocrinology. 1985. PMID: 2865689
-
Somatostatin content of the median eminence in female rats with lesion-induced disruption of the inhibitory control of growth hormone secretion.Endocrinology. 1978 Sep;103(3):817-25. doi: 10.1210/endo-103-3-817. Endocrinology. 1978. PMID: 744118
-
Effect of lesions in the periventricular nucleus of the preoptic-anterior hypothalamus on growth hormone and thyrotropin secretion and brain somatostatin.Brain Res. 1981 Oct 19;222(2):267-76. doi: 10.1016/0006-8993(81)91032-5. Brain Res. 1981. PMID: 6116518
-
[A hypothalamic hormone-somatostatin--from endocrinology to neurophysiology].Nihon Naibunpi Gakkai Zasshi. 1992 May 20;68(5):507-25. doi: 10.1507/endocrine1927.68.5_507. Nihon Naibunpi Gakkai Zasshi. 1992. PMID: 1353733 Review. Japanese.
-
Somatostatin secretion and action in the regulation of growth hormone secretion.Metabolism. 1990 Sep;39(9 Suppl 2):43-5. doi: 10.1016/0026-0495(90)90208-t. Metabolism. 1990. PMID: 1976219 Review.
Cited by
-
Tanycytes and the Control of Thyrotropin-Releasing Hormone Flux Into Portal Capillaries.Front Endocrinol (Lausanne). 2019 Jun 25;10:401. doi: 10.3389/fendo.2019.00401. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31293518 Free PMC article. Review.
-
TRH: pathophysiologic and clinical implications.Acta Neurochir (Wien). 1985;75(1-4):43-8. doi: 10.1007/BF01406322. Acta Neurochir (Wien). 1985. PMID: 3922203
-
Somatostatin and somatostatin receptor physiology.Endocrine. 2003 Apr;20(3):255-64. doi: 10.1385/ENDO:20:3:255. Endocrine. 2003. PMID: 12721505 Review.
-
Hypothalamic control of GH secretion: pathophysiology and clinical implications.Acta Neurochir (Wien). 1985;75(1-4):60-71. doi: 10.1007/BF01406324. Acta Neurochir (Wien). 1985. PMID: 2859744
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources